Form 8-K - Current report:
SEC Accession No. 0001193125-25-021403
Filing Date
2025-02-06
Accepted
2025-02-06 08:59:47
Documents
18
Period of Report
2025-02-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d914912d8k.htm   iXBRL 8-K 54364
2 EX-3.1 d914912dex31.htm EX-3.1 8157
3 EX-3.2 d914912dex32.htm EX-3.2 79282
4 EX-4.1 d914912dex41.htm EX-4.1 21849
5 EX-99.1 d914912dex991.htm EX-99.1 7945
9 GRAPHIC g914912g0206105038584.jpg GRAPHIC 3672
  Complete submission text file 0001193125-25-021403.txt   345727

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20250206.xsd EX-101.SCH 2837
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20250206_lab.xml EX-101.LAB 18738
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20250206_pre.xml EX-101.PRE 11698
20 EXTRACTED XBRL INSTANCE DOCUMENT d914912d8k_htm.xml XML 3843
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 25595625
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)